Cancer name Prostate Cancer
Cancer Type PRAD
Immunotherapy type Cancer Vaccine
Treatment pAdxsi?GFP?PSMA
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature HLA-DR
Official Symbol NA
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description On day 8, the DCs in the trans<U+2011>fection and non<U+2011>transfection groups all showed features of mature DCs (high expression of the co<U+2011>stimulatory and MHC II molecules); the expression levels of CD80, CD83, CD86 and HLA<U+2011>DR were significantly higher in the transfected DCs than in the non<U+2011>transfected DCs (P<0.05).
PMID 26783185
Title Antitumor effect of dendritic cells transfected with prostate-specific membrane antigen recombinant adenovirus on prostate cancer: An in vitro study.